<DOC>
	<DOCNO>NCT01446952</DOCNO>
	<brief_summary>This Phase 1 , open-label , non-randomized , dose-finding , study Vitamin E δ-Tocotrienol subject resectable pancreatic tumor .</brief_summary>
	<brief_title>Vitamin E δ-Tocotrienol ( VEDT ) Single Dose Healthy Subjects</brief_title>
	<detailed_description>Vitamin E tocotrienols show exhibit cancer-preventive activity preclinical study . Vitamin E tocotrienols compose α- , β- , δ- , γ-tocotrienols . The investigator preclinical study indicate δ-tocotrienol posse potent antitumor activity pancreatic cancer . It believe micronutrient may role prevention pancreatic cancer healthy participant increase risk develop disease .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>The participant ≥ 18 year old The participant Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . The participant adequate organ function follow : Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min . Bilirubin ≤ institutional upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within institutional normal range . Absolute neutrophil count ( ANC ) ≥ 1000mm³ Platelet count ≥ 100,000/mm³ The participant capability understand informed consent document sign informed consent document . Sexually active participant ( male female ) must use medically acceptable method contraception course study . Female participant childbearing potential must negative pregnancy test screening . Able understand comply requirement protocol . The participant receive investigational therapy ( investigational therapy study ) . The participant receive investigational therapy within 30 day prior first dose study drug . Patients unable swallow capsule . Patients prior malignancy , squamous basal cell carcinoma , unless disease free ≥ 5 year . The participant prior major surgery within 30 day prior first dose study drug . The participant active infection fever &gt; 38.5C within 3 day prior first dose study drug . The participant uncontrolled intercurrent illness include , limited , ongoing active infection , hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The participant unable unwilling stop taking vitamin , herbal remedy , nonprescription medication . The participant pregnant breastfeeding . The participant unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>prevention</keyword>
	<keyword>pancreas</keyword>
</DOC>